The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study

详细信息    查看全文

• 作者：Franç ; ois Chasset ; MD^a ; Laurent Arnaud ; MD ; PhD^b ; ^c ; Nathalie Costedoat-Chalumeau ; MD ; PhD^d ; ^e ; Noel Zahr ; PharmD ; PhD^f ; Didier Bessis ; MD^g ; Camille Francè ; s ; MD^a ; ^{camille.frances@tnn.aphp.fr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：antimalarials ; cutaneous lupus erythematosus ; hydroxychloroquine ; hydroxychloroquine blood concentration ; increasing dose ; retinal toxicity
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：74
• 期：4
• 页码：693-699.e3
• 全文大小：469 K

文摘

Up to 30% of patients with cutaneous lupus erythematosus (CLE) fail to respond to hydroxychloroquine (HCQ).

Objectives

We sought to evaluate the efficacy of increased daily doses of HCQ on cutaneous response in refractory CLE.

Methods

We conducted an open-label prospective study between 2010 and 2014. Patients with CLE and HCQ blood level less than or equal to 750 ng/mL were included. The daily dose of HCQ was increased to reach blood concentrations greater than 750 ng/mL. The primary end point was the number of responders defined by an improvement of CLE Disease Area and Severity Index score (4 points or 20% decrease) in patients with HCQ blood concentration greater than 750 ng/mL.

Results

We included 34 patients (26 women; median age 45 [range 28-72] years). Two nonadherent patients were excluded. The median CLE Disease Area and Severity Index score before treatment was significantly improved after treatment (8 [range 2-30] vs 1.5 [range 0-30]), P < .001). The primary response criterion was reached in 26 (81%) of the 32 patients analyzed. A decrease in HCQ doses without further CLE flare (median follow-up 15.8 [range 3.06-77.4] months) was achieved in 15 of the 26 responders.

Limitations

The main limitations of the study are its open-label design and the limited number of patients included.

Conclusions

Increasing HCQ doses to reach blood concentrations greater than 750 ng/mL should be considered before addition of other treatments in refractory CLE.